Too little, too soon: Japan's experiment in regenerative medicine deregulation
- PMID: 37419104
- DOI: 10.1016/j.stem.2023.06.005
Too little, too soon: Japan's experiment in regenerative medicine deregulation
Abstract
In 2013, Japan established a conditional approval pathway for cell and gene therapies. Our analysis of the four products approved via this pathway identifies evidence suggesting shortcomings in safety and efficacy data submitted by the sponsors and raises concerns about whether this pathway is delivering on its promise.
Keywords: Japan; biomedical regulation; cell therapy; conditional approval; ethics; expedited pathways; gene therapy; health policy; post-market studies; regenerative medicine.
Copyright © 2023 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests J.E.J.R. has served as an investigator in clinical trials sponsored by Cynata Therapeutics, Australia, developing allogeneic cell therapies and other sponsored cell and gene therapy trials over two decades.
MeSH terms
LinkOut - more resources
Full Text Sources
